Integrated Diagnostics Holdings PLC IDH CEO increases stake in the Company (1555R)
2023年10月25日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMIDHC
RNS Number : 1555R
Integrated Diagnostics Holdings PLC
25 October 2023
IDH CEO increases stake in the Company
25 October 2023
(Cairo and London) - Integrated Diagnostics Holdings ("IDH,"
"the Group," or "the Company"), a leading provider of diagnostics
services with operations in Egypt, Jordan, Nigeria, Sudan, and soon
launching in Saudi Arabia, announced today that its Chief Executive
Officer, Dr. Hend El Sherbini, has completed the purchase of an
additional 2.0 million shares in the Company. The purchases were
completed between 10 October 2023 and 16 October 2023 by Hena
Holdings Limited ("Hena Holdings"), the vehicle through which Dr.
El Sherbini owns her shares, and were announced on the London Stock
Exchange (LSE).
Hena Holdings remains the single largest shareholder in the
Company with 162.4 million shares and a stake of 27.07%, up from
the previously held 26.71% stake. Dr. El Sherbini had previously
purchased additional shares in the Company in August 2022,
acquiring 7.3 million shares and increasing her stake in the
Company to 26.71% from 25.50% (which she had held since the
Company's initial IPO).
Commenting on the purchase, Dr. Hend El Sherbini, said: "The
decision to further increase my stake in the Company underscores my
confidence in the strength and resilience of IDH's business model
and in its growth potential over the coming years. Despite the
ongoing economic uncertainty, the Company has continued to perform
well, delivering robust growth and solid profitability while making
progress on our post-Covid-19 growth and value creation strategy.
In the coming months, we will be adding a fifth geography to our
portfolio, bringing our superior quality and expertise to thousands
of Saudi Arabian patients. We are excited for what lies ahead as we
continue to expand our footprint, service offering and capabilities
to generate sustainable growth and value for our stakeholders and
capitalise on the important growth opportunities offered by our
markets."
It is important to note that the stock purchases were completed
before the start of the closed period leading up to the release of
IDH's 9M 2023 earnings report.
In addition to Hena Holdings' purchases, Lord St John of Bletso,
IDH's Chairman of the Board of Directors completed the purchase of
30 thousand shares in the Company earlier this year. Ms. Yvonne
Stillhart, a member of the Board of Directors also purchased 230
thousand shares in the Company in April of this year. It is worth
highlighting that transactions completed by Hena Holdings, Lord St
John of Bletso, and Ms. Yvonne Stillhart were conducted on the
London Stock Exchange.
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading diagnostics services provider in the Middle
East and Africa offering a broad range of pathology and radiology
tests to patients in Egypt, Jordan, Nigeria and Sudan. The Group's
core brands include Al Borg, Al-Borg Scan and Al Mokhtabar in
Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan
(both in Sudan) and Echo-Lab (Nigeria). A long track record for
quality and safety has earned the Company a trusted reputation, as
well as internationally recognised accreditations for its portfolio
of over 2,000 diagnostics tests. From its base of 552 branches as
of 31 December 2022, IDH served over 8.7 million patients and
performs more than 32.7 million tests in 2022. IDH will continue to
add laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group's expansion plans include acquisitions in
new Middle Eastern, African, and East Asian markets where its model
is well-suited to capitalise on similar healthcare and consumer
trends and capture a significant share of fragmented markets. IDH
has been a Jersey-registered entity with a Standard Listing on the
Main Market of the London Stock Exchange (ticker: IDHC) since May
2015 with a secondary listing on the EGX since May 2021 (ticker:
IDHC.CA). Learn more at idhcorp.com .
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
LEI: 2138007JN9NUWKKTS790
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPGBCUUPWGAC
(END) Dow Jones Newswires
October 25, 2023 02:00 ET (06:00 GMT)
Integrated Diagnostics (LSE:IDHC)
過去 株価チャート
から 8 2024 まで 9 2024
Integrated Diagnostics (LSE:IDHC)
過去 株価チャート
から 9 2023 まで 9 2024